Palvella Therapeutics
Ms. McGowan brings over 35 years of diversified financial experience in the pharmaceutical and biotech industry.
Before Palvella, Ms. McGowan served as Chief Financial Officer of VaxInnate, a private company developing vaccines for influenza, malaria, and dengue. Prior to VaxInnate, she led financial operations at Tobira Therapeutics (acquired by Allergan plc), a clinical-stage company developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Earlier in her career, Ms. McGowan held financial senior management roles at Discovery Laboratories, Inc. (now Windtree Therapeutics), Claneil Enterprises, Liposome Company (acquired by Elan Corp.), and Johnson & Johnson. She received her B.S. in finance and accounting from Drexel University and holds an M.B.A. in finance from Fairleigh Dickinson University.
This person is not in any offices
Palvella Therapeutics
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases.